Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.

NEW YORK, Feb. 25, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hum ...

Tiziana Life Sciences ( ($TLSA) ) has shared an update. On February 25, 2025, Tiziana Life Sciences announced the nearing completion of a ...

GFP ioMicroglia enables real-time tracking of microglia in complex co-cultures and in vivo, streamlining neurodegeneration ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded ...

Ivor Elrifi, CEO of Tiziana Life Sciences, commented, “Partnering with Renaissance is a significant milestone in our mission ...

Alzheimer’s disease remains one of the most pressing medical mysteries of our time. Despite decades of research, scientists are still uncovering the complex mechanisms behind this ... Continue Reading ...

The study, led by Dr. Stanley Stevens, a professor in the Department of Molecular Biosciences in the USF College of Arts in Sciences, will be the first of its kind to develop and use a chimeric mouse ...

Stochastic modelling is the development of mathematical models for non-deterministic physical systems, which can adopt many possible behaviours starting from any given initial condition. Monte ...